Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Nature Reviews Clinical Oncology – Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Nature Reviews Clinical Oncology – Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Abstract. First-generation KRAS G12C inhibitors, such as sotorasib and adagrasib, are limited by the depth and duration of clinical responses. One potential explanation for their…
Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.
The healthcare sector’s necessary transition towards electronic health records (EHRs) has transformed patient care and operational efficiency. To access this subscriber-only content please log in…
An abstract is unavailable.
9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal cancer, as well as other…
Microbe enhances cancer immunotherapy in mouse study
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
Finding out you have cancer is hard, but telling the ones you love can be even harder.
Abstract. Improved cancer screening and treatment programs have led to an increased survivorship of patients with cancer, but consequently also to the rise in number…